Titles

  • Co-Director CHUM Microbiome Centre
  • Research member at the Montreal Cancer Institute
  • Assistant Professor, Department of Hematology & Oncology, Université de Montréal
  • Clinician Scientist, Cancer Axis, CHUM Research Center

Research Angle

  • We are a translational oncology lab focused on developing and advancing novel microbiome-based therapeutics in oncology.

Laboratory Team

  • Gabryella Pinheiro PhD, Postdoctoral Research Fellow
  • Sebastian Hunter MSc, Staff Computational Biologist and Bioinformatician
  • Alysé Filin BSc, Research Assistant
  • Rasteh Nili, PhD student
  • Sreya Duttagupta, PhD candidate (co-supervision with Dr. Bertrand Routy MD PhD)
  • Claudia Sayed BSc, Melanoma Biobank Research Coordinator
  • Edmond Rafie, MD, Resident

Recent Publications

  1. Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation
  2. Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
  3. Intratumoral Escherichia Is Associated with Improved Survival to Immune Checkpoint Inhibitors in Lung Cancer 
  4. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

Pubmed Page

Full Bibliography

Email address for application

Arielle.elkrief.med@ssss.gouv.qc.ca

Biography

Dr. Arielle Elkrief MD, FRCPC is a clinician-scientist, Assistant Professor in the Department of Oncology at the Centre hospitalier de l’Université de Montréal (CHUM), and Co-Director of the CHUM Microbiome Centre. She was recruited to the CRCHUM in 2023 and directs her research laboratory focused on the gut and tumor microbiome as a biomarker of response to immunotherapy. She leads microbiome-centered clinical trials combining microbiome interventions such as fecal microbiota transplantation (FMT), prebiotics, and diet. In addition, she contributed to establishing the negative impact of antibiotics on immunotherapy activity in patients with cancer. She was recently awarded the American Society of Clinical Oncology Young Investigator Award and the Society of Immunotherapy of Cancer-Melanoma Research Alliance Women in Melanoma Award. She has published over 75 papers in journals including the Journal of Clinical Oncology, Nature Medicine, Journal of Thoracic Oncology, Annals of Oncology, and Clinical Cancer Research.